Title: | Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation
![]() |
keywords: |
Transcriptome or Gene expression
|
ID: |
PRJNA229460
|
description: |
Previously, we have identified the polypeptide N-acetylgalactosaminyltransferase 3 (GALNT3) gene as notably hypomethylated in low-malignant potential (LMP) and high-grade (HG) serous epithelial ovarian tumors, compared to normal ovarian tissues. Here we show that GALNT3 is strongly overexpressed in both LMP and HG serous EOC tumors, thus suggesting that epigenetic mechanisms might be implicated in GALNT3 overexpression in serous epithelial ovarian cancer (EOC). Moreover, GALNT3 expression significantly correlated with shorter progression-free survival (PFS) periods in serous EOC patients with advanced disease. Knockdown of the GALNT3 expression in EOC cells led to sharp decrease of cell proliferation and induced S-phase cell cycle arrest. Additionally, GALNT3 suppression significantly inhibited EOC cell migration and invasion. Gene expression profiling and consecutive network and pathway analyses confirmed these findings, as numerous genes and pathways known previously to be implicated in ovarian tumorigenesis, including EOC tumor invasion and metastasis, were found to be downregulated upon GALNT3 suppression, while some tumor suppressor genes were induced. Moreover, GALNT3 downregulation was associated with reduced MUC1 protein expression in EOC cells, probably related to destabilization of the MUC1 protein due to lack of GALNT3 glycosylation activity.Taken together, our data are indicative for a strong oncogenic potential of the GALNT3 gene in advanced EOC and identify this transferase as a novel EOC biomarker and putative EOC therapeutic target. Our findings also suggest that GALNT3 overexpression might contribute to ovarian etiology through aberrant mucin O-glycosylation.
Overall design: To better understand the molecular mechanisms of GALNT3 gene action in ovarian cancer cells, we employed the Agilent Whole Human Genome microarrays, containing ~ 44,000 genes to identify global gene expression changes upon GALNT3 suppression in A2780s cells. We compared the gene expression of the previously selected clone shRNA- GALNT3-knockdown clones 1 & 2 (sh-cl1 & sh-cl2) against the corresponding control (ctrl) clone. The microarray experiments were performed in duplicates, as four hybridizations were carried out for the GALNT3-suppressing cell clones against the corresponding control, using a fluorescent dye reversal (dye-swap) technique.
|
accesstypes: |
download
|
landingpage: | http://www.ncbi.nlm.nih.gov/bioproject/PRJNA229460 |
authentication: |
none
|
authorization: |
none
|
ID: |
pmid:24504219
|
name: |
Homo sapiens
|
ncbiID: |
ncbitax:9606
|
abbreviation: |
NCBI
|
homePage: | http://www.ncbi.nlm.nih.gov |
ID: |
SCR:006472
|
name: |
National Center for Biotechnology Information
|
homePage: | http://www.ncbi.nlm.nih.gov/bioproject |
ID: |
SCR:004801
|
name: |
NCBI BioProject
|
Inhibition of RUNX2 transcriptional activity blocks the proliferation, migr...
Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits ...
BCAT1 expression associates with ovarian cancer progression : BCAT1 express...
LY75 modulates epithelial to mesenchymal transition and metastatic potentia...